June 7, 2017 11:29 AM EDTUpdated June 8, 04:59 PM
R&D

No­var­tis posts land­mark CAR-T da­ta as head-to-head ri­val­ry with Kite Phar­ma looms

John Carroll

Editor & Founder

Vas­ant Narasimhan, chief med­ical of­fi­cer of No­var­tis AG, looks on dur­ing a Jan­u­ary 2017 news con­fer­ence in Basel

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times